IBSA UK&I, the UK subsidiary of Swiss pharmaceutical company IBSA, has assumed direct responsibility for the commercialisation and distribution of ialuril® in the United Kingdom and Ireland from 9 April 2026, according to Irish Medical Times.

The transition brings ialuril®, a Class III medical device used for intravesical instillation to support restoration of the bladder glycosaminoglycan layer, under direct management by IBSA UK&I, aligning it with the company's expanding uro-gynaecology portfolio, which includes Hyaluxelle® and Perovial®.

Steven Knapp, general manager of IBSA UK&I, said: "This transition reflects IBSA's growing commitment to the urology and uro-gynaecology therapy area and allows us to work more closely with healthcare professionals and NHS partners. Our focus is on ensuring continuity of supply and strengthening the support we provide to clinicians so that patients can continue to access effective treatment."

Oxford Pharmacy Store has been appointed as IBSA UK&I's primary NHS distribution partner, handling orders and supply to NHS customers. Ialuril® will also remain available through AAH Pharmaceuticals and Alliance as alternative distribution channels.

The move follows IBSA's establishment of its UK affiliate in 2022 and marks the conclusion of a decade-long partnership with Aspire Pharma, which represented IBSA across the UK and Ireland. IBSA acknowledged Aspire Pharma's contribution during the longstanding collaboration.

Ialuril® is indicated for conditions associated with disruption of the bladder GAG layer, including recurrent urinary tract infections, interstitial cystitis, bladder pain syndrome, and chemical or radiation-induced cystitis. There is no change to the product's formulation, presentation, or clinical use.

Access the full announcement for further detail on the ialuril® transition and IBSA UK&I's uro-gynaecology portfolio.